The global demand for Pneumococcal Conjugate Vaccine Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Pneumococcal conjugate vaccine is used to prevent severe pneumococcal infection in children and adults. Pneumococcal diseases include pneumonia, a condition of the lungs, ear infections, sinus, meningitis, and bacteremia. This vaccine protects against 13 types of bacteria that cause pneumococcal disease. It is administered for all children younger than two years old, and people two years or older (adults 65 years or older) with certain medical conditions. People with any life-threatening allergic reaction to any component of the vaccine is not considered as suitable. This vaccine is made an integral part of the routine childhood immunization schedule worldwide.
Pneumococcal disease, one of the leading vaccine-preventable disorders, and one of the major causes of young children’s mortality rate worldwide is the key trend driving this market’s growth. The demand for this vaccine is on the rise since it effectively prevents antibiotic-resistant pneumococcal infections caused by vaccine serotypes and the spread of the bacteria in the community. Increased awareness programs initiated by the government agencies and rising production of novel vaccines will boost the market growth. Improving access to the vaccine for economically backward communities by the various distribution channels set up by government agencies and NGOs will expand the market reach. The high costs and the long duration involved in vaccines’ production will be the significant restraints hurting market growth.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of pneumococcal conjugate vaccine.
The entire pneumococcal conjugate vaccine market has been sub-categorized into product type, sector and distribution channel. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
By Product Type
By Distribution Channel
- Prevnar 13
- Pneumovax 23
- Distribution Partner Companies
- Non-Governmental Organizations (NGO)
- Government Authorities
This section covers regional segmentation which accentuates on current and future demand for pneumococcal conjugate vaccine market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Pneumococcal Conjugate Vaccine Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the pneumococcal conjugate vaccine market include Glaxosmithkline plc, LG Chem Ltd., Merck & Co., Inc., Panacea Biotec Limited, Pfizer Inc., Pnuvax Incorporated, Serum Institute of India Pvt. Ltd., Shenzhen Kangtai Biological Products Co., Ltd., Beijing Minhai Biotechnology Corporation Limited, SK Bioscience, Walvax Biotechnology Co., Ltd. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.